Aurobac Therapeutics SAS (Aurobac), announced today the appointment of Florence Séjourné as Chief Executive Officer. Aurobac is a joint venture recently created by Boehringer Ingelheim, Evotec SE and bioMérieux, focusing on the development of a new precision medicine approach, from diagnosis to cure to fight Antimicrobial Resistance (AMR). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/aurobac-therapeutics-appoints-florence-sejourne-as-chief-executive-officer-6215